LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Developed for Acute Typhoid Fever

By LabMedica International staff writers
Posted on 05 Jul 2017
Print article
Salmonelloses are a group of potentially fatal bacteremias caused by different serovars of Salmonella enterica. Typhoid fever (TF) caused by the human-specific serovar S. typhi, is a global health problem, especially in developing countries.

Accurate diagnosis of salmonellosis remains a challenge in endemic settings. Clinically, initial presentation with typhoid or non-typhoid Salmonella (NTS) disease is usually with non-differentiating fever alone, and often without symptoms of gastroenteritis that would indicate a Salmonella infection.

An international team of scientists led by those at the University of California Irvine (Irvine, CA, USA) designed a retrospective study was using a convenience series of sera samples from Nigerian pediatric febrile cases and healthy controls, as well as other infectious diseases from other locations outside Nigeria. The Nigerian samples were collected between 2009 and 2014 from children aged eight months to 13 years (median approximately 4 years) who presented to primary or secondary health centers in central and northwest Nigeria with an acute febrile illness and other symptoms that were suggestive of bacteremia.

Blood was obtained aseptically from a peripheral vein for blood culture and simultaneously an aliquot for serum separation was saved. Bacteria were identified by morphology, and for Enterobacteriacae, by use of an API 20 E rapid identification system. Lipopolysaccharides microarrays were obtained from various species and printed on Oncyte Avid nitrocellulose-coated glass slides using an Omnigrid 100 array printer, and printed at a concentration of 0.1 μg/mL. Immunoglobulin A (IgA), IgM and IgG enzyme-linked immunosorbent assays (ELISAs) using S.enterica serovar Typhi (S. typhi) lipopolysaccharide (LPS) and hemolysin E (t1477) protein were conducted.

The scientists found that the most expedient discrimination was achieved between TF and healthy children. LPS-specific IgA and IgM provided receiver operator characteristic areas under the curve (ROC AUC) values of 0.963 and 0.968, respectively, and 0.978 for IgA+IgM combined. Similar performance was achieved with t1477-specific IgA and IgM (0.968 and 0.968, respectively; 0.976 combined). Importantly, discrimination between TF and children with other infections was maintained by LPS-specific IgA and IgM (AUC = 0.903 and 0.934, respectively; 0.938 combined), and slightly reduced for IgG (0.909), while t1477-specific IgG performed best (0.914).

The authors concluded that the key finding concerns LPS. This is a common cell-wall component present in many bacterial species. Yet despite this, S. Typhi LPS-specific IgA and IgM are excellent markers of acute TF in Nigerian children, and insensitive to other non-salmonelloses. This surprising finding suggests a rapid point-of-care test for TF can be developed based on detection of LPS-specific IgA+IgM. The study was published on June 22, 2017, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
University of California Irvine

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.